Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus + fulvestrant in endocrine-pretreated advanced breast cancer after prior mTOR inhibitor treatment
2013-000665-36Phase 2Completed
- Sponsor
- UZ Brussel
- Start
- Jul 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of everolimus and fulvestrant in breast cancer, sponsored by UZ Brussel. Primary endpoint: 4-month clinical benefit rate. Started Jul 2013; status: completed.
02
Drugs
everolimusfulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2013-000665-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000665-36.